Trademark: 88004821
Word
M MICROBIX
Status Date
Tuesday, April 9, 2024
Filing Date
Monday, June 18, 2018
Published for Opposition
Tuesday, April 9, 2024
9 laboratory instruments for the detection pathogens and toxins in a biological sample for research use; Instruments for the processing of cells and cell derived materials, namely, flow cytometers and flow-based analyzers that detect and analyze nucleic acid content for scientific, laboratory, and general research use; laboratory instruments that detect pathogens in a biological sample for research use; Instruments for the processing of cells and cell derived materials
5 urokinase used to treat blood clots; Thrombolytic drugs, namely, plasminogen activating drugs and fibrinolytic drugs; urokinase preparations for the restoration of patency to central venous catheters obstructed by clotted blood or fibrin; urokinase preparations for treating pulmonary embolism; urokinase preparations for treating the lysis of acute pulmonary emboli and pulmonary emboli accompanied by unstable hemodynamics; urokinase preparations for treating thrombosis; urokinase preparations for treating coronary artery thrombosis; urokinase preparations for treating myocardial infarction; urokinase preparations for the lysis of thrombi; urokinase preparations for treating peripheral arterial and graft thromboembolic occlusion; urokinase preparations for treating deep vein thrombosis; urokinase preparations for treating pleural effusions; urokinase preparations for treating peripheral arterial occlusion; urokinase preparations for treating ischemic stroke; urokinase preparations for treating lower limb ischemia; test samples used in conjunction with laboratory diagnostics in the nature of biological or biochemical samples used to verify the reliability of laboratory equipment; test samples used in conjunction with assay methods in the nature of biological or biochemical assay samples used to verify the reliability of laboratory tests; Liquid, frozen and lyophilized inactivated, native pathogens, including whole and fragmented eukaryotes, prokaryotes, and viruses, independent and in host cells, all for in vitro and in vivo scientific or diagnostic use; inactivated, native pathogens, namely, liquid, frozen or lyophilized recombinant DNA and/or RNA preparations, either purified or within host organisms, in various buffers, singly and in combination, all for in vitro and in vivo scientific or diagnostic use; Positive controls, namely, reagents for use with nucleic-acid-based, immunologic, or other diagnostic tests to confirm proper test operation, and run in conjunction with patient samples run to confirm, assess, test, or verify the operation of the test method; proficiency test samples in the nature of biological test samples used to test the proficiency of technicians who use infectious disease diagnostics test systems to determine the pathogenic or biochemical content of samples; Diagnostic reagents in the nature of biotechnology products for medical and veterinary use, namely, micro-organisms for amplification controls; Diagnostic kits for in-vitro scientific and diagnostic use; Laboratory assay kits for scientific and diagnostic use; Biological material for scientific or diagnostic purposes, in the nature of serum and plasma from infected and disease state individuals used for verification and validation of human diagnostic assays for such infections and diseases; Biotechnology products for scientific or diagnostic purposes, namely, reagents and solutions in the nature of viruses, bacteria, fungi, parasites, and derivatives thereof used to research, develop, manufacture, and validate infectious disease diagnostic tests; biochemical products, namely, antibodies for scientific or research use; diagnostic reagents containing lyophilized microorganisms, and reagents containing lyophilized microorganisms all for in-vitro use and for use in biochemistry, clinical chemistry and microbiology; diagnostic reagents for scientific research use; diagnostic reagents for medical research use; diagnostic preparations for clinical laboratory use; diagnostic preparations for medical laboratory use; diagnostic preparations for medical research use; diagnostic preparations for scientific research use
1 Biochemical agents for in vitro and in vivo scientific or diagnostic use, namely, viruses, bacteria, parasites, and purified and unpurified whole, fragmented, and fractionated pathogens and pathogenic organisms; Cells and cell culture derived products for in vitro or in vivo scientific or diagnostic use, namely, for production of organisms, proteins, nucleic acids, or cellular fractions used as reagents or antigens, test articles, or controls; antibodies and thrombolytics for in vitro scientific or research use; Biochemicals in the form of monoclonal antibodies for in vitro scientific use; Biochemicals in the form of monoclonal antibodies for research use; Active Pharmaceutical Ingredients to stimulate blood-clot dissolving processes; Microbial antigens and antisera for in vitro diagnostic use
45 Licensing of process technology used in the manufacturing of vaccines
44 Animal husbandry services; animal breeding services; sperm- and semen-sexing services in the nature of in vitro fertilization services; biological cell-selection services for medical purposes in the nature of in vitro fertilization services; medical services in the field of in vitro fertilization, namely, services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells
10 automated flow cytometer sample introduction accessories used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multiwell laboratory plates; medical apparatus for the automated analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus for the automated cytometric analysis of cells in the nature of cytometers for medical diagnostic use; medical apparatus in the nature of cytometers that detect atypia in cells for medical diagnostic use; medical apparatus for automated analysis of nuclear features for the detection of neoplasms and cancer and genetic conditions; apparatus for medical diagnostic uses in the nature of an automated flow cytometer sample introduction accessory, namely, a machine which is used in conjunction with a flow cytometer to deliver biological and chemical samples from single test tubes and multi-well laboratory plates
42 Providing diagnostic testing services, laboratory tests; production for others of cells, cell lines, viruses, bacteria, and pathogens, proteins, or nucleic acids in whole or in part; Research and development services in the field of process technology used in the manufacture of vaccines; process technology services to be used in the manufacture of a vaccine; biological cell-selection services for biological research purposes; biological research services of delivering energy to a population of biological cells for the purpose of selecting desired cells and negatively selecting undesired cells
The mark consists of "MICROBIX" underneath a stylized "M".
Apr 9, 2024
Official Gazette Publication Confirmation E-Mailed
Apr 9, 2024
Published For Opposition
Mar 20, 2024
Notification Of Notice Of Publication E-Mailed
Mar 1, 2024
On Hold - Electronic Record Review Required
Feb 22, 2024
Approved For Pub - Principal Register
Feb 20, 2024
Examiner's Amendment Entered
Feb 20, 2024
Notification Of Examiners Amendment E-Mailed
Feb 20, 2024
Examiners Amendment E-Mailed
Feb 20, 2024
Examiners Amendment -Written
Jan 30, 2024
Teas/Email Correspondence Entered
Jan 30, 2024
Correspondence Received In Law Office
Jan 30, 2024
Teas Response To Office Action Received
Dec 28, 2023
Notification Of Non-Final Action E-Mailed
Dec 28, 2023
Non-Final Action E-Mailed
Dec 28, 2023
Non-Final Action Written
Oct 25, 2023
Teas/Email Correspondence Entered
Oct 25, 2023
Correspondence Received In Law Office
Oct 24, 2023
Teas Response To Suspension Inquiry Received
Jul 26, 2023
Notification Of Inquiry As To Suspension E-Mailed
Jul 26, 2023
Inquiry To Suspension E-Mailed
Jul 26, 2023
Suspension Inquiry Written
Jul 6, 2023
Suspension Checked - To Attorney For Action
Dec 14, 2022
Notification Of Letter Of Suspension E-Mailed
Dec 14, 2022
Letter Of Suspension E-Mailed
Dec 14, 2022
Suspension Letter Written
Dec 12, 2022
Teas/Email Correspondence Entered
Dec 12, 2022
Correspondence Received In Law Office
Dec 12, 2022
Assigned To Lie
Dec 5, 2022
Teas Response To Suspension Inquiry Received
Jun 9, 2022
Notification Of Inquiry As To Suspension E-Mailed
Jun 9, 2022
Inquiry To Suspension E-Mailed
Jun 9, 2022
Suspension Inquiry Written
May 25, 2022
Suspension Checked - To Attorney For Action
Oct 20, 2021
Notification Of Letter Of Suspension E-Mailed
Oct 20, 2021
Letter Of Suspension E-Mailed
Oct 20, 2021
Suspension Letter Written
Oct 12, 2021
Teas/Email Correspondence Entered
Oct 12, 2021
Correspondence Received In Law Office
Oct 5, 2021
Teas Response To Suspension Inquiry Received
Apr 8, 2021
Notification Of Inquiry As To Suspension E-Mailed
Apr 8, 2021
Inquiry To Suspension E-Mailed
Apr 8, 2021
Suspension Inquiry Written
Mar 24, 2021
Suspension Checked - To Attorney For Action
Jun 12, 2020
Notification Of Letter Of Suspension E-Mailed
Jun 12, 2020
Letter Of Suspension E-Mailed
Jun 12, 2020
Suspension Letter Written
Jun 10, 2020
Teas/Email Correspondence Entered
Jun 10, 2020
Correspondence Received In Law Office
Jun 5, 2020
Teas Response To Suspension Inquiry Received
Dec 9, 2019
Notification Of Inquiry As To Suspension E-Mailed
Dec 9, 2019
Inquiry To Suspension E-Mailed
Dec 9, 2019
Suspension Inquiry Written
Dec 4, 2019
Suspension Checked - To Attorney For Action
Nov 15, 2019
Assigned To Lie
Apr 24, 2019
Notification Of Letter Of Suspension E-Mailed
Apr 24, 2019
Letter Of Suspension E-Mailed
Apr 24, 2019
Suspension Letter Written
Apr 11, 2019
Teas/Email Correspondence Entered
Apr 10, 2019
Correspondence Received In Law Office
Apr 10, 2019
Teas Response To Office Action Received
Oct 10, 2018
Notification Of Non-Final Action E-Mailed
Oct 10, 2018
Non-Final Action E-Mailed
Oct 10, 2018
Non-Final Action Written
Oct 4, 2018
Assigned To Examiner
Jun 22, 2018
New Application Office Supplied Data Entered
Jun 21, 2018
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
